Evonik's Leadership and Dividend Overhaul Face Shareholder Vote

Evonik shares trade at a premium despite analyst skepticism. A pivotal shareholder vote in June will decide a new dividend policy and confirm leadership, setting the course for its turnaround.

The stock of German specialty chemicals group Evonik is trading at a puzzling premium. Despite a 28% surge since the start of the year, pushing shares to €17.06, a significant gap remains between the market price and analyst targets. Jefferies and Deutsche Bank Research see fair value at €15.10 and €15.00, respectively. This disconnect suggests investors are betting on an operational turnaround that analysts have yet to fully endorse.

A major test of that confidence arrives on June 3, 2026, at the annual general meeting. Shareholders will vote on a pivotal reset of the company's dividend policy and confirm key leadership appointments. The proposed dividend for fiscal 2025 is set at €1.00 per share, down from €1.17 the previous year. Starting in 2026, payouts will be strictly tied to adjusted net income, with a target payout ratio between 40% and 60%. This move, aimed at debt reduction and financial flexibility, is seen by analysts as overdue fiscal discipline but means lower short-term returns for investors.

Adding stability to the strategic shift, the company has filled a key vacancy. Michael Rauch will assume the CFO role on May 1, 2026. The 54-year-old brings 16 years of experience from Henkel and most recently served as interim CEO at Swiss firm Selecta. Jefferies analyst Helena Xu stated that Rauch must solidify investor trust in the group's capital allocation. In a parallel move, the supervisory board extended the contract of CEO Christian Kullmann, who has led Evonik since May 2017, until 2030. The formal confirmation for Kullmann will also occur at the June shareholder meeting.

Operational performance remains a mixed bag, providing the context for these strategic and personnel decisions. The recent share price strength is largely attributed to disciplined pricing in the methionine business. However, other divisions like Specialty Additives and Nutrition & Care have yet to show a clear volume recovery. The upcoming first-quarter report on May 8 will be scrutinized for signs of demand improvement in these segments.

From a technical perspective, the stock's Relative Strength Index (RSI) sits near 30, indicating an oversold condition even after the year's strong advance. Chart resistance is seen around €17.30, while support lies near €14.80, bolstered by the longer-term moving average.

The convergence of a new dividend framework, a solidified management team, and the need for tangible operational progress sets a decisive stage for Evonik. The shareholder vote in June won't answer whether the current market premium is justified, but it will determine if the company's restructuring course gains formal approval to proceed.